You are currently here:

You are here


You are here


Extended basic page

Explore other content within Areas of Focus  

Block before Body

Treating a Rare Lung Disease

Lymphangioleiomyomatosis (LAM) is a rare, progressive, cystic disease of the lungs. It is associated with declining lung function and almost exclusively affects women. The average age of diagnosis is approximately 35 years.

On this page, you'll find more information about the condition, its diagnosis and treatment, and links to helpful resources.

Blocks after Body

Disease Education Information

What Is LAM?

LAM is a genetic disorder that can be inherited with tuberous sclerosis complex (TSC-LAM) or can be sporadic (S-LAM). It is caused by mutations in genes called tuberous sclerosis complex genes (TSC1 or TSC2). This results in a deficiency or dysfunction of the genes’ protein products, hamartin or tuberin, which leads to inappropriate cell growth and proliferation, particularly of smooth muscle-like cells called LAM cells, which infiltrate the lungs and lymphatics. Changes in the lungs obstruct air flow and can lead to other significant, potentially life-threatening problems.

Who Gets LAM?

TSC-LAM occurs in up to 40% of women with tuberous sclerosis complex, while S-LAM affects approximately three to five women per million in the general population.

What Are the Symptoms of LAM?

Patients affected by LAM most commonly develop progressive shortness of breath with exertion, recurrent cases of collapsed lung (pneumothorax), and chylous fluid collections around the lungs.

On average, women with LAM have symptoms for three to five years, and have had an average of 2.2 incidents of pneumothorax before the diagnosis is made. In patients with this disease, lung function tests show reduced air flow rates and diffusion capacity. Patients can also have abdominal tumors that include angiomyolipomas of the kidney and lymphangiomyomas.

How Is LAM Diagnosed?

Pulmonary LAM can be diagnosed using high-resolution CT imaging, which will typically show round, thin-walled cysts throughout the lungs, together with some features of TSC.

A lung biopsy may be required for diagnosis in cases in which TSC is absent. A blood test for a biomarker called serum vascular endothelial growth factor-D may also be helpful in the diagnosis of LAM because levels of that factor have been found to be elevated in most women who have LAM.

Can LAM Be Treated?

In some countries, there is an approved therapy for patients with LAM that has been shown to stabilize lung function. This therapy belongs to a class of medications called mTOR inhibitors, which block cell growth and proliferation.

Other types of medications have been used in the treatment of LAM, although they remain unproven. Supportive care may include supplemental oxygen. If lung function markedly declines, lung transplantation may be an option for some patients.

Block After Mid Section

Pfizer Rare Disease Resources for Lymphangioleiomyomatosis (LAM)

For Healthcare Professionals
PfizerPro offers information on treatments for LAM and other rare diseases.
Pfizer Rare Disease Consortium
Pfizer is focusing on collaborations with world-class R&D organizations to advance and speed rare disease treatment innovations. The Pfizer Rare Disease Consortium in the UK, our first center of excellence in rare disease research, is a model for future collaborations in Europe and the US.
Rare Disease Research
A deeper understanding of the genetics of rare diseases gives us an opportunity to explore breakthrough science, new approaches and pioneering collaborations to potentially deliver next-generation therapies for people living with rare diseases.